Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Survey of BK virus screening practices by American society of transplantation members.

Tan CS, Gabardi S, Pavlakis M.

Clin Transplant. 2019 Jun 1:e13620. doi: 10.1111/ctr.13620. [Epub ahead of print] No abstract available.

PMID:
31152561
2.

Priming effects in the crystallization of the phase change compound GeTe from atomistic simulations.

Gabardi S, Sosso GG, Behler J, Bernasconi M.

Faraday Discuss. 2019 Feb 18;213(0):287-301. doi: 10.1039/c8fd00101d.

PMID:
30379974
3.

Post-Renal Transplantation Outcomes in Elderly Patients Compared to Younger Patients in the Setting of Early Steroid Withdrawal.

Alsheikh R, Gabardi S.

Prog Transplant. 2018 Dec;28(4):322-329. doi: 10.1177/1526924818800039. Epub 2018 Sep 13.

PMID:
30213228
4.

New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines.

Gabardi S, Pavlakis M, Tan C, Francis J, Cardarelli F, Asch W, Bodziak K, Chobanian M, Gilligan H, Gohh R, Kung SC, Inker L, Martin S, Rodig N, Rossi A, Chandraker A.

Transpl Infect Dis. 2018 Dec;20(6):e12985. doi: 10.1111/tid.12985. Epub 2018 Sep 19.

PMID:
30175491
5.

Early aspirin use and the development of cardiac allograft vasculopathy.

Kim M, Bergmark BA, Zelniker TA, Mehra MR, Stewart GC, Page DS, Woodcome EL, Smallwood JA, Gabardi S, Givertz MM.

J Heart Lung Transplant. 2017 Dec;36(12):1344-1349. doi: 10.1016/j.healun.2017.06.015. Epub 2017 Jul 3.

PMID:
28781013
6.

CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.

Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR.

Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1321-1336. doi: 10.2215/CJN.13221216. Epub 2017 Jun 2. Review.

7.

Causes and Consequences of the Worldwide Belatacept Shortage.

Gabardi S, van Gelder T.

Transplantation. 2017 Jul;101(7):1520-1521. doi: 10.1097/TP.0000000000001763. No abstract available.

PMID:
28376033
8.

Use of polyclonal/monoclonal antibody therapies in transplantation.

Yeung MY, Gabardi S, Sayegh MH.

Expert Opin Biol Ther. 2017 Mar;17(3):339-352. doi: 10.1080/14712598.2017.1283400. Epub 2017 Jan 30. Review.

PMID:
28092486
9.

Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus.

Krenzien F, Quante M, Heinbokel T, Seyda M, Minami K, Uehara H, Biefer HRC, Schuitenmaker JM, Gabardi S, Splith K, Schmelzle M, Petrides AK, Azuma H, Pratschke J, Li XC, ElKhal A, Tullius SG.

Am J Transplant. 2017 May;17(5):1242-1254. doi: 10.1111/ajt.14087. Epub 2016 Nov 21.

10.

Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.

Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.

Transpl Infect Dis. 2016 Dec;18(6):904-912. doi: 10.1111/tid.12609. Epub 2016 Nov 7.

11.

Micafungin treatment and eradication of candiduria among hospitalized patients.

Gabardi S, Martin S, Sura M, Mohammed A, Golan Y.

Int Urol Nephrol. 2016 Nov;48(11):1881-1885. Epub 2016 Sep 1.

PMID:
27587066
12.

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.

Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV.

PLoS One. 2016 Jul 14;11(7):e0158431. doi: 10.1371/journal.pone.0158431. eCollection 2016.

13.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Riella LV, Gabardi S, Azzi J.

N Engl J Med. 2016 Jun 30;374(26):2599-600. doi: 10.1056/NEJMc1602859. No abstract available.

PMID:
27355545
14.

Influence of the exchange and correlation functional on the structure of amorphous InSb and In3SbTe2 compounds.

Gabardi S, Caravati S, Los JH, K├╝hne TD, Bernasconi M.

J Chem Phys. 2016 May 28;144(20):204508. doi: 10.1063/1.4950817.

15.

Nephrotoxicity of Natural Products.

Nauffal M, Gabardi S.

Blood Purif. 2016;41(1-3):123-9. doi: 10.1159/000441268. Epub 2016 Jan 15. Review.

16.

A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Krenzien F, ElKhal A, Quante M, Rodriguez Cetina Biefer H, Hirofumi U, Gabardi S, Tullius SG.

Transplantation. 2015 Nov;99(11):2258-68. doi: 10.1097/TP.0000000000000842. Review.

17.

Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly.

Gabardi S, Tullius SG, Krenzien F.

Curr Opin Organ Transplant. 2015 Aug;20(4):424-30. doi: 10.1097/MOT.0000000000000220. Review.

PMID:
26126198
18.

Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products?

Phillips K, Reddy P, Gabardi S.

J Pharm Pract. 2017 Feb;30(1):9-16. doi: 10.1177/0897190015585758. Epub 2016 Jul 9. Review.

PMID:
26043743
19.

Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.

Gabardi S, Ramasamy S, Kim M, Klasek R, Carter D, Mackenzie MR, Chandraker A, Tan CS.

Transpl Infect Dis. 2015 Aug;17(4):536-43. doi: 10.1111/tid.12402. Epub 2015 Jun 26.

20.

Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation.

Maldonado AQ, Tichy EM, Rogers CC, Campara M, Ensor C, Doligalski CT, Gabardi S, Descourouez JL, Doyle IC, Trofe-Clark J.

Am J Health Syst Pharm. 2015 May 15;72(10):781-93. doi: 10.2146/ajhp140476. Review.

PMID:
25941253
21.

Generic immunosuppression in transplantation: current evidence and controversial issues.

El Hajj S, Kim M, Phillips K, Gabardi S.

Expert Rev Clin Immunol. 2015 May;11(5):659-72. doi: 10.1586/1744666X.2015.1026895. Epub 2015 Mar 30. Review.

PMID:
25817258
22.

Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.

Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.

Transplantation. 2015 Jul;99(7):1499-505. doi: 10.1097/TP.0000000000000570.

PMID:
25643140
23.

Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.

Riella LV, Safa K, Yagan J, Lee B, Azzi J, Najafian N, Abdi R, Milford E, Mah H, Gabardi S, Malek S, Tullius SG, Magee C, Chandraker A.

Transplantation. 2014 Jun 27;97(12):1247-52. doi: 10.1097/01.TP.0000442782.98131.7c.

PMID:
24854670
24.

Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options.

Kim M, Martin ST, Townsend KR, Gabardi S.

Pharmacotherapy. 2014 Jul;34(7):733-44. doi: 10.1002/phar.1426. Epub 2014 Apr 19. Review.

PMID:
24753207
25.

Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates.

Kim M, Townsend KR, Wood IG, Boukedes S, Guleria I, Gabardi S, El-Chemaly S, Camp PC, Chandraker AK, Milford EL, Goldberg HJ.

Am J Respir Crit Care Med. 2014 May 15;189(10):1234-9. doi: 10.1164/rccm.201312-2160OC.

PMID:
24749479
26.

Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations.

Rostas S, Kim M, Gabardi S.

Prog Transplant. 2014 Mar;24(1):33-6. doi: 10.7182/pit2014521. Review.

PMID:
24598563
27.

Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.

Martin ST, Cardwell SM, Nailor MD, Gabardi S.

Am J Transplant. 2014 Apr;14(4):788-96. doi: 10.1111/ajt.12649. Epub 2014 Mar 4.

28.

Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.

Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R.

Clin Nephrol. 2015 Feb;83(2):125-9. doi: 10.5414/CN108163.

PMID:
24495904
29.

Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial.

Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, Mandelbrot DA, Adey DB, Heher E, Fan PY, Conte S, Dyer-Ward C, Chandraker A.

Clin J Am Soc Nephrol. 2014 Mar;9(3):583-9. doi: 10.2215/CJN.04230413. Epub 2014 Jan 30.

30.

Call for antimicrobial stewardship in solid organ transplantation.

Aitken SL, Palmer HR, Topal JE, Gabardi S, Tichy E.

Am J Transplant. 2013 Sep;13(9):2499. doi: 10.1111/ajt.12364. Epub 2013 Jul 19. No abstract available.

31.

Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients.

Gabardi S, Townsend K, Martin ST, Chandraker A.

Transpl Infect Dis. 2013 Aug;15(4):361-8. doi: 10.1111/tid.12087. Epub 2013 May 6.

PMID:
23647907
32.

Mycophenolate fetal toxicity and risk evaluation and mitigation strategies.

Kim M, Rostas S, Gabardi S.

Am J Transplant. 2013 Jun;13(6):1383-9. doi: 10.1111/ajt.12238. Epub 2013 Apr 25. Review.

33.

Risk evaluation and mitigation strategies: a focus on belatacept.

Sam T, Gabardi S, Tichy EM.

Prog Transplant. 2013 Mar;23(1):64-70. doi: 10.7182/pit2013122.

PMID:
23448823
34.

A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.

Gabardi S, Tichy EM.

Prog Transplant. 2013 Mar;23(1):58-62; quiz 63. doi: 10.7182/pit2013816.

PMID:
23448822
35.

Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.

Gabardi S.

Prog Transplant. 2013 Mar;23(1):55-7. doi: 10.7182/pit2013235.

PMID:
23448821
36.

Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs.

van Gelder T, Gabardi S.

Transpl Int. 2013 Aug;26(8):771-7. doi: 10.1111/tri.12074. Epub 2013 Feb 27. Review.

37.

Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.

Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR.

Transpl Infect Dis. 2013 Apr;15(2):163-70. doi: 10.1111/tid.12036. Epub 2012 Dec 12.

PMID:
23230972
38.

Current trends in immunosuppressive therapies for renal transplant recipients.

Lee RA, Gabardi S.

Am J Health Syst Pharm. 2012 Nov 15;69(22):1961-75. doi: 10.2146/ajhp110624. Review.

PMID:
23135563
39.

Density functional simulations of Sb-rich GeSbTe phase change alloys.

Gabardi S, Caravati S, Bernasconi M, Parrinello M.

J Phys Condens Matter. 2012 Sep 26;24(38):385803. doi: 10.1088/0953-8984/24/38/385803. Epub 2012 Sep 4.

PMID:
22945279
40.

Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.

Gabardi S, Olyaei A.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1054-64. doi: 10.1345/aph.1R071. Epub 2012 Jul 17. Review.

PMID:
22811345
41.

Dyslipidemia and its therapeutic challenges in renal transplantation.

Riella LV, Gabardi S, Chandraker A.

Am J Transplant. 2012 Aug;12(8):1975-82. doi: 10.1111/j.1600-6143.2012.04084.x. Epub 2012 May 11. Review.

42.

Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.

Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A.

Clin Transplant. 2012 May-Jun;26(3):E184-90. doi: 10.1111/j.1399-0012.2012.01624.x. Epub 2012 Apr 8.

PMID:
22487221
43.

Influenza in solid organ transplant recipients.

Martin ST, Torabi MJ, Gabardi S.

Ann Pharmacother. 2012 Feb;46(2):255-64. doi: 10.1345/aph.1Q436. Epub 2012 Jan 10. Review.

PMID:
22234989
44.

Immunosuppression, generic drugs and the FDA.

Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR.

Am J Transplant. 2012 Mar;12(3):792-3; author reply 794. doi: 10.1111/j.1600-6143.2011.03875.x. Epub 2011 Dec 17. No abstract available.

45.

An update on risk evaluation and mitigation strategies in transplantation.

Gabardi S, Halloran PF, Friedewald J.

Am J Transplant. 2012 Jan;12(1):257-8. doi: 10.1111/j.1600-6143.2011.03809.x. Epub 2011 Oct 25. No abstract available.

46.

Generic maintenance immunosuppression in solid organ transplant recipients.

Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA.

Pharmacotherapy. 2011 Nov;31(11):1111-29. doi: 10.1592/phco.31.11.1111. Review.

PMID:
22026398
47.

Understanding risk evaluation and mitigation strategies in organ transplantation.

Gabardi S.

Pharmacotherapy. 2011 Jul;31(7):714-22. doi: 10.1592/phco.31.7.714. Review.

PMID:
21923459
48.

Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.

Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.

Pharmacotherapy. 2011 Jun;31(6):566-73. doi: 10.1592/phco.31.6.566.

PMID:
21923440
49.

Managing risk in developing transplant immunosuppressive agents: the new regulatory environment.

Gabardi S, Halloran PF, Friedewald J.

Am J Transplant. 2011 Sep;11(9):1803-9. doi: 10.1111/j.1600-6143.2011.03653.x. Epub 2011 Aug 9.

50.

Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.

Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM.

Ann Pharmacother. 2011 Sep;45(9):e48. doi: 10.1345/aph.1Q019. Epub 2011 Aug 2.

PMID:
21811001

Supplemental Content

Loading ...
Support Center